Kumud Kalia, serving as the Chief Information Officer for Guardant Health, Inc. (NASDAQ:GH), has formally disclosed a sequence of transactions involving the firm's common stock. The reported activity indicates a net position adjustment through both sales and acquisitions. Kalia executed a total sale of $157,164 in shares. The transaction prices for these sales were recorded between $130.86 and $131.08 per share. In a concurrent move, Kalia acquired $78,456 worth of shares at a single price point of $130.76.
The timeline of these transactions reveals specific execution dates. On June 10, 2026, Kalia sold 600 shares of common stock at $130.86 per share. Following this sale, Kalia purchased 600 shares on June 15, 2026, at $130.76 per share. On that same date, an additional sale of 600 shares occurred at $131.08 per share. The net result of these specific short-swing transactions required Kalia to remit $192 in recoverable Section 16(b) profits to Guardant Health. Post-transaction, Kalia’s direct holding stands at 40,814 shares of Guardant Health common stock.
Market performance for Guardant Health has been notable during this period. The stock has climbed to $149.92. This price level represents a 188% return over the preceding year. Current valuation data indicates the stock is trading near its 52-week high of $153.95. According to InvestingPro analysis, the current market price suggests the stock is overvalued relative to its calculated Fair Value.
External developments surrounding Guardant Health include significant regulatory milestones. The company recently secured FDA approval for the Guardant360 CDx test. This test has been designated as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS treatment. The approval allows the blood-based test to identify patients with specific mutations who may benefit from the therapy. Additionally, the American Cancer Society has recommended the Shield blood test for colorectal cancer screening.
Analyst sentiment has responded positively to these developments. Mizuho raised its price target for Guardant Health to $175. This adjustment followed the FDA approval and the American Cancer Society recommendation. Bernstein upgraded the stock rating, citing potential revenue growth that may exceed consensus estimates for upcoming years. RBC Capital and Goldman Sachs initiated coverage with positive ratings. Goldman Sachs set a price target of $165, highlighting growth drivers such as the FDA approval and upcoming product launches. RBC Capital set a price target of $185.
Investors seeking deeper insights into Guardant Health’s valuation and performance metrics can access a comprehensive Pro Research Report. This report is available for Guardant Health and over 1,400 other US equities on InvestingPro. The Fair Value calculator utilizes a mix of 17 proven industry valuation models to assess stock potential.